Jason D Goldman, David C B Lye, David S Hui, Kristen M Marks, Raffaele Bruno, Rocio Montejano, Christoph D Spinner, Massimo Galli, Mi-Young Ahn, Ronald G Nahass, Yao-Shen Chen, Devi SenGupta, Robert H Hyland, Anu O Osinusi, Huyen Cao, Christiana Blair, Xuelian Wei, Anuj Gaggar, Diana M Brainard, William J Towner, Jose Muñoz, Kathleen M Mullane, Francisco M Marty, Karen T Tashima, George Diaz, Aruna Subramanian
BACKGROUND: Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS: We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days...
May 27, 2020: New England Journal of Medicine